Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis

Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis

The benefit of adjuvant trastuzumab treatment in patients with HER2-positive breast tumors ≤ 10 mm without lymph node involvement (T1abN0) is insufficiently investigated. The aim of this systematic review and meta-analysis was to examine if adjuvant trastuzumab improves the prognosis in these patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Critical reviews in oncology/hematology 2023-04, Vol.184, p.103952-103952, Article 103952
Hauptverfasser: Hassing, Christina M.S., Nielsen, Dorte Lisbet, Knoop, Ann Søegaard, Tvedskov, Tove Holst Filtenborg, Kroman, Niels, Lænkholm, Anne-Vibeke, Juhl, Carsten Bogh, Kümler, Iben
Format: Artikel
Sprache:eng
Schlagworte:
Adjuvants, Immunologic
Breast cancer
Breast Neoplasms - pathology
Chemotherapy, Adjuvant
Disease-Free Survival
Female
Human epidermal growth factor receptor 2 (HER2)
Humans
Meta-analysis
Prognosis
Receptor, ErbB-2
T1abN0
Trastuzumab
Trastuzumab - therapeutic use
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The benefit of adjuvant trastuzumab treatment in patients with HER2-positive breast tumors ≤ 10 mm without lymph node involvement (T1abN0) is insufficiently investigated. The aim of this systematic review and meta-analysis was to examine if adjuvant trastuzumab improves the prognosis in these patients. Databases were searched to identify interventional and observational studies evaluating the effect of trastuzumab on breast cancer specific survival (BCSS), disease free survival (DFS), distant recurrence free survival (DRFS), overall survival (OS) or recurrence free survival (RFS). Twelve studies examining the effect of trastuzumab and nine control studies without trastuzumab were identified (n = 6927). Median follow-up was 36–123 months. Significantly improved DFS (Hazard Ratio (HR) 0.14, p 
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2023.103952